PAM
SRNE

Pegasus Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Pegasus Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,000
Closed -$94K – 74
2020
Q2 		$94K Hold
15,000
– – 0.06% 68
2020
Q1 		$28K Hold
15,000
– – 0.02% 65
2019
Q4 		$51K Buy
+15,000
New +$35.8K 0.03% 70
2018
Q1 		– Sell
-15,000
Closed -$57K – 70
2017
Q4 		$57K Buy
+15,000
New +$39.1K 0.06% 68

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pegasus Asset Management's SRNE Position: Q3 2020 in Review

Pegasus Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 15,000 shares — an estimated $94K sold.

Pegasus Asset Management first reported a position in SRNE in Q4 2017 and held it in 4 quarters. The position peaked at $94K in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Pegasus Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Pegasus Asset Management sold 15,000 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $94K.
  • Pegasus Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
  • Pegasus Asset Management's Sorrento Therapeutics, Inc. position peaked at $94K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Pegasus Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.